These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 18094029

  • 1. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 2. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 3. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 4. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 5. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A, Fujimoto S, Iwatsubo S, Kawachi H, Kitamura K.
    Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
    [Abstract] [Full Text] [Related]

  • 6. [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome].
    Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M.
    Cas Lek Cesk; 1999 Oct 20; 138(18):560-4. PubMed ID: 10596472
    [Abstract] [Full Text] [Related]

  • 7. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
    Bayorh MA, Mann G, Walton M, Eatman D.
    Clin Exp Hypertens; 2006 Feb 20; 28(2):121-32. PubMed ID: 16546838
    [Abstract] [Full Text] [Related]

  • 8. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
    Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M.
    J Pharmacol Exp Ther; 2010 Mar 20; 332(3):1072-80. PubMed ID: 19940106
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats.
    Burla AK, Neves MF, Oigman W, Mandarim-de-Lacerda CA.
    Int J Cardiol; 2007 Jan 02; 114(1):64-70. PubMed ID: 16650491
    [Abstract] [Full Text] [Related]

  • 10. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
    Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertension; 2008 Mar 02; 51(3):734-41. PubMed ID: 18227404
    [Abstract] [Full Text] [Related]

  • 11. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH.
    Circulation; 2003 Oct 14; 108(15):1831-8. PubMed ID: 14517164
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    Am J Nephrol; 2004 Oct 14; 24(2):242-9. PubMed ID: 15031627
    [Abstract] [Full Text] [Related]

  • 13. Enalapril prevents fatty liver in nephrotic rats.
    Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F.
    J Nephrol; 2002 Oct 14; 15(4):358-67. PubMed ID: 12243364
    [Abstract] [Full Text] [Related]

  • 14. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul 14; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 15. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.
    Tsuboi N, Kawamura T, Okonogi H, Ishii T, Hosoya T.
    J Renin Angiotensin Aldosterone Syst; 2012 Mar 14; 13(1):113-7. PubMed ID: 21729991
    [Abstract] [Full Text] [Related]

  • 16. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun 14; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 17. Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome.
    Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M.
    Med Sci Monit; 2002 Feb 14; 8(2):BR69-74. PubMed ID: 11859270
    [Abstract] [Full Text] [Related]

  • 18. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
    Mavrakanas TA, Cheva A, Kallaras K, Karkavelas G, Mironidou-Tzouveleki M.
    Pharmacology; 2010 Feb 14; 86(2):85-91. PubMed ID: 20689340
    [Abstract] [Full Text] [Related]

  • 19. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.
    Am J Physiol Renal Physiol; 2009 Sep 14; 297(3):F802-8. PubMed ID: 19535572
    [Abstract] [Full Text] [Related]

  • 20. Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
    Liang W, Chen C, Shi J, Ren Z, Hu F, van Goor H, Singhal PC, Ding G.
    Nephrol Dial Transplant; 2011 Mar 14; 26(3):789-99. PubMed ID: 20729265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.